Table 2.
FLC Patient Demographics and Clinical Characteristics.
| Variable | Classification | Overall | Fibrolamellar Registry | Johns Hopkins & UT Southwestern |
|---|---|---|---|---|
| Number of Patients | 19 | 11 | 8 (6 JH, 2 UTSW) | |
| Age at Diagnosis (years) | Mean = 22.9 (SD = 6.1) |
Mean = 20.7 (SD = 6.0) |
Mean = 25.875 (SD = 5.1) |
|
| Gender | Male | 12 (63.2%) | 7 (63.6%) | 5 (62.5%) |
| Female | 7 (36.8%) | 4 (36.4%) | 3 (37.5%) | |
| FLC Stage at Diagnosis | BCLC A | 3 (15.8%) | 3 (27.3%) | 0 (0%) |
| BCLC B | 4 (21.1%) | 3 (27.3%) | 1 (12.5%) | |
| BCLC C | 12 (63.2%) | 5 (45.5%) | 7 (87.5%) | |
| FLC Stage at ICI Treatment | BCLC A | 0 (0%) | 0 (0%) | 0 (0%) |
| BCLC B | 1 (5.3%) | 1 (9.1%) | 0 (0%) | |
| BCLC C | 18 (94.7%) | 10 (90.9%) | 8 (100%) | |
| Number of Patients Receiving Various Treatments |
Prior Systemic Treatment | 15 (78.9%) | 9 (81.8%) | 6 (75.0%) |
| Prior Surgery | 13 (68.4%) | 7 (63.6%) | 6 (75.0%) | |
| Prior Local Radiation | 4 (21.1%) | 2 (18.2%) | 2 (25.0%) | |
| Number of Prior Systemic Treatments |
Median = 1 (range 0–8) |
Median = 2 (range 0–8) |
Median = 1 (range 0–5) |
|
| Prior Sorafenib | 9 (47.3%) | 9 (81.8%) | 0 (0%) | |
| Treatment Setting | Academic | 18 | 10 (90.9%) | 8 (100%) |
| Community | 1 | 1 (9.1%) | 0 (0%) |